News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Senator Durbin, SIU Medicine leaders express concerns about federal budget cuts

Health care leaders and Senator Dick Durbin gathered at SIU School of Medicine on July 25 to strongly denounce sweeping federal budget cuts to Medicaid, student loan support and medical research—pillars that sustain both local patient care and the next generation of physicians.
News

Strength in recovery: Letting lived experience lead the way

When Mandy Hagen stepped onstage to accept the Rising Star Award in addiction services, it marked a full-circle moment. Once unsure whether she deserved a seat at the table, today she’s leading recovery efforts across four counties in southern Illinois and inspiring others to find their way forward.
News

Strength in recovery: Letting lived experience lead the way

When Mandy Hagen stepped onstage to accept the Rising Star Award in addiction services, it marked a full-circle moment. Once unsure whether she deserved a seat at the table, today she’s leading recovery efforts across four counties in southern Illinois and inspiring others to find their way forward.
News

Strength in recovery: Letting lived experience lead the way

When Mandy Hagen stepped onstage to accept the Rising Star Award in addiction services, it marked a full-circle moment. Once unsure whether she deserved a seat at the table, today she’s leading recovery efforts across four counties in southern Illinois and inspiring others to find their way forward.
Trial
Psychiatry

ITI-007-321: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients with Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder

Active recruiting
The primary objective is to evaluate the efficacy of lumateperone administered orally for at least 26 weeks in pediatric patients with schizophrenia (aged 13 to 17 years) or pediatric patients with bipolar disorder (aged 10 to 17 years), or pediatric patients with irritability associated with autism spectrum disorder (ASD) (aged 5 to 17 years).
Subscribe to Patient